The success of anti-BAFF treatment in reducing meningeal inflammation and preventing cortical neuronal damage in our study and in treating other autoimmune diseases warrant further study of its efficacy as a potential therapy for MS. The gene discussed is TNFSF13B; the disease is autoimmune disease.